Related Experiment Videos
Hologram quantitative structure activity relationship studies on 5-HT6 antagonists
Munikumar Reddy Doddareddy1, Yeon Joo Lee, Yong Seo Cho
1Biochemicals Research Center, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea.
Bioorganic & Medicinal Chemistry
|June 24, 2004
Summary
Quantitative structure-activity relationship models predict the activity of arylsulfonamide compounds as 5-HT6 antagonists. These hologram quantitative structure-activity relationship (HQSAR) models demonstrate strong predictive power for drug discovery.
Area of Science:
- Medicinal Chemistry
- Computational Chemistry
- Pharmacology
Background:
- 5-HT6 receptor antagonists are investigated for potential therapeutic applications.
- Arylsulfonamide compounds have shown promise as 5-HT6 antagonists.
- Predictive modeling is crucial for optimizing drug candidates.
Purpose of the Study:
- To develop predictive hologram quantitative structure-activity relationship (HQSAR) models for arylsulfonamide 5-HT6 antagonists.
- To validate the predictive performance of the developed HQSAR models.
- To elucidate atomic contributions to compound activity using HQSAR.
Main Methods:
- Development of HQSAR models using training sets of arylsulfonamide compounds.
- Fragment distinction based on atoms, bond, and connectivity with fragment size 4-7.
- Validation of models using external test sets.
Main Results:
- The best HQSAR model for specific antagonists achieved q2=0.702 and r2=0.971, with predictive r2=0.678 on an external set.
- A second HQSAR model for diverse antagonists showed q2=0.693 and r2=0.923, with predictive r2=0.692 on an external set.
- Contribution maps identified key atomic influences on 5-HT6 antagonist activity.
Conclusions:
- HQSAR is an effective method for predicting the activity of 5-HT6 antagonists.
- The developed models provide insights into structure-activity relationships for arylsulfonamides.
- This approach aids in the rational design of novel 5-HT6 antagonist drug candidates.